Table 3.
Changes in clinical, laboratory, and drug therapy values after 6 month dapaglifozin.
| Variable | Baseline | 6 Months | p |
|---|---|---|---|
| Body Mass Index kg/m2 * | 27.3 ± 4.6 | 27.0 ± 4.4 | 0.017 |
| Systolic BP mmHg | 114 ± 16 | 112 ± 13 | 0.27 |
| Haemoglobin g/L | 14.3 ± 1.5 | 14.4 ± 1.6 | 0.44 |
| Creatinine mg/dL * | 1.17 ± 0.3 | 1.24 ± 0.4 | 0.028 |
| eGFR mL/min/1.73 m2 * | 69 ± 21 | 64 ± 20 | 0.03 |
| Sodium mEq/L | 140 ± 4 | 140 ± 3 | 0.51 |
| Potassium mEq/L | 4.5 ± 0.5 | 4.5 ± 0.5 | 0.39 |
| Natriuretic peptides * pg/mL | 778 [425–1688] | 648 [268–1320] | <0.001 |
| Echo | |||
| PAPs mm * | 32 ± 10 | 28 ± 7 | <0.001 |
| E/e’ * | 14 ± 5 | 10 ± 3 | <0.001 |
| TAPSE | 20 ± 3 | 20 ± 3 | 0.72 |
| Drug therapy | |||
| Furosemide mg/day * | 39 ± 34 | 31 ± 37 | 0.001 |
| BB (% of target) | 51 ± 31 | 51 ± 32 | 0.42 |
| ARNI * (% of target) | 54 ± 39 | 63 ± 37 | 0.003 |
| MRAs (% of target) | 41 ± 38 | 42 ± 39 | 0.84 |
Data are expressed as mean ± SD (standard deviation) or median [interquartile range]. * p < 0.05; ARNI: angiotensin receptor–neprilysin inhibitors, BB: beta blockers, BP: blood pressure, eGFR: estimated glomerular filtration rate (calculated by CKD-epi formula), MRAs: aldosterone receptor antagonists, PAPs: pulmonary artery systolic pressure, and TAPSE: tricuspid annular plane excursion.